Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

BACKGROUND: Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery. METHODS: This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Yoo, Changhoon, Lee, Sang Soo, Song, Ki Byung, Jeong, Jae Ho, Hyung, Jaewon, Park, Do Hyun, Song, Tae Jun, Seo, Dong Wan, Lee, Sung Koo, Kim, Myung-Hwan, Lee, Seung Soo, Kim, Jin Hee, Jin, Hyung-seung, Park, Jin-hong, Hwang, Dae Wook, Lee, Jae Hoon, Lee, Woohyung, Chang, Heung-Moon, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Kim, Song Cheol
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403346/
https://ncbi.nlm.nih.gov/pubmed/32433600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0867-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados